BDX - Becton, Dickinson and Company
| Previous Close | 245.12 |
| Open | 245.45 |
| Bid | 205.50 x 1000 |
| Ask | 0.00 x 1000 |
| Day's Range | 244.25 - 248.40 |
| 52 Week Range | 208.62 - 265.87 |
| Volume | 2,251,547 |
| Avg. Volume | 1,457,095 |
| Market Cap | 66.705B |
| Beta (3Y Monthly) | 1.26 |
| PE Ratio (TTM) | 74.15 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.08 (1.26%) |
| Ex-Dividend Date | 2019-06-06 |
| 1y Target Est | N/A |
- PR Newswire•4 days ago
BD Statement on FDA Circulatory System Devices Panel Regarding Paclitaxel-Coated Devices
Additionally, BD presented its own data confirming that the benefits outweigh the risks for LUTONIX® Drug-Coated Balloons (DCBs) in SFA. Over the past several months, BD has been working diligently to obtain all available patient follow up data and collaborating with FDA, professional clinical organizations and industry to investigate the important issue of DCB safety.
- PR Newswire•20 days ago
BD Announces Pricing and Upsizing of Tender Offers
FRANKLIN LAKES, N.J. , June 4, 2019 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the " Company " or " BD ") today announced the consideration payable in connection with ...
- PR Newswire•20 days ago
New Report Sheds Light on Health Care's 'Hidden' Epidemic - Hospital Drug Diversion - and its Role in the Opioid Crisis
FRANKLIN LAKES, N.J., June 4, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today released a new report based on an independent national survey that examines drug diversion in U.S. hospitals, an underreported contributor to the opioid epidemic. Hospital drug diversion, when a health care worker "diverts" opiates or other controlled substances away from patients for personal use or sale, remains a significant challenge that is largely underdiscussed. Denial of the problem in their own hospitals – Executives and providers (nurses, pharmacists and anesthesiologists) may be in denial about the diversion problem in their own facilities.
- PR Newswire•20 days ago
BD Announces Early Tender Results
FRANKLIN LAKES, N.J. , June 3, 2019 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX) (the " Company " or " BD ") today announced the early tender results for its previously ...
- PR Newswire•24 days ago
BD to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
FRANKLIN LAKES, N.J. , May 31, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Goldman Sachs ...
- PR Newswire•last month
Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
FRANKLIN LAKES, N.J., May 20, 2019 /PRNewswire/ -- Becton, Dickinson and Company (BDX) (the "Company" or "BD") today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, the "Securities" and each a "series"). The Company reserves the right, but is under no obligation, to increase any of the Tender SubCaps in the table above or the aggregate tender cap at any time, subject to applicable law.
- PR Newswire•2 months ago
BD Announces Results for 2019 Second Fiscal Quarter; Updates Fiscal 2019 Guidance
- As reported, revenues of $4.195 billion decreased 0.6 percent. - On a comparable, currency-neutral basis, revenues increased 3.4 percent. - As reported, diluted earnings per share of $(0.07) increased ...
- PR Newswire•2 months ago
BD to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
FRANKLIN LAKES, N.J. , May 1, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Bank of America ...
- PR Newswire•2 months ago
BD Receives FDA Approval for Fully Sterile Chlorhexidine Gluconate Antiseptic Skin Preparation
New BD ChloraPrep™ Skin Preparation is the Only Commercially Available CHG Antiseptic Skin Preparation with Sterile Solution Designation in the U.S. FRANKLIN LAKES, N.J., April 30, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) approval for BD ChloraPrep™ skin preparation with sterile solution, the only fully sterile chlorhexidine gluconate (CHG) antiseptic skin preparation commercially available in the U.S.
- PR Newswire•2 months ago
BD Board Declares Dividends
FRANKLIN LAKES, N.J. , April 29, 2019 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.77 per common share, payable on June ...
- PR Newswire•3 months ago
BD Unveils Platelet Quality Control Media to Help Reduce the Incidence of Sepsis in Patients Requiring Platelet Transfusion
BD BACTEC™ Platelet Quality Control Media is cleared by the U.S. Food and Drug Administration and CE-IVD marked for platelet testing FRANKLIN LAKES, N.J. , April 8, 2019 /PRNewswire/ -- BD (Becton, Dickinson ...
- PR Newswire•3 months ago
BD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call
FRANKLIN LAKES, N.J. , April 4, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2019 earnings conference ...
- PR Newswire•3 months ago
BD Launches New Automated Flow Cytometry Sample Preparation Instrument with CE-IVD Certification
BD FACSDuet™ system raises the bar on flow cytometry automation offering a fully integrated sample-to-answer solution with the BD FACSLyric™ clinical flow cytometer FRANKLIN LAKES, N.J. , March 26, 2019 ...
- PR Newswire•3 months ago
BD Statement on Paclitaxel-Coated Devices
On March 15, the FDA issued a letter to health care providers regarding paclitaxel-coated devices used to treat peripheral arterial disease in the femoropopliteal artery. It is of critical importance that BD's customers and shareholders know that BD believes in its LUTONIX® drug-coated balloon (DCB) formulation and stands behind the robustness of its pre-clinical and clinical data.
- PR Newswire•3 months ago
BD Receives U.S. FDA Approval for First Venous Stent to Treat Iliofemoral Venous Occlusive Disease
Venovo™ Venous Stent proven safe and effective in iliac and femoral veins FRANKLIN LAKES, N.J. , March 14, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical ...
- PR Newswire•4 months ago
BD to Present at the Barclays Global Healthcare Conference
FRANKLIN LAKES, N.J. , March 4, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Barclays Global ...
- PR Newswire•4 months ago
BD to Present at Leerink Partners 8th Annual Global Healthcare Conference
FRANKLIN LAKES, N.J. , Feb. 15, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at Leerink Partners ...
- GlobeNewswire•4 months ago
Research Report Identifies Becton, Dickinson, MUELLER WATER PRODUCTS, Spartan Motors, The Providence Service, Heska, and Lithia Motors with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•5 months ago
BD Announces Results for 2019 First Fiscal Quarter; Reaffirms Fiscal 2019 Guidance
- As reported, revenues of $4.160 billion increased 35.1 percent. - On a comparable, currency-neutral basis, revenues increased 5.2 percent. - As reported, diluted earnings per share of $2.05 increased ...
- PR Newswire•5 months ago
BD Launches Ergonomic Pen Needle Technology to Help Optimize Injection Technique
BD Nano™ Second Generation Pen Needle Receives 510(k) Clearance from U.S. Food and Drug Administration FRANKLIN LAKES, N.J. , Jan. 24, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), ...
- PR Newswire•5 months ago
BD Announces Preliminary Results For 2019 First Fiscal Quarter; Reaffirms Fiscal 2019 Guidance
- Preliminary reported revenues of $4.160 billion increased 35.1 percent. - On a comparable, currency-neutral basis, preliminary revenues increased 5.2 percent. - As reported, preliminary diluted earnings ...
- PR Newswire•5 months ago
BD Announces Webcast of Annual Meeting of Shareholders
FRANKLIN LAKES, N.J. , Jan. 15, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology company, announced today that it will host a live webcast of its Annual ...
- PR Newswire•5 months ago
BD Announces Live Webcast Of First Fiscal Quarter Earnings Conference Call
FRANKLIN LAKES, N.J. , Jan. 8, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2019 earnings conference ...
- PR Newswire•6 months ago
BD to Present at Investor Healthcare Conferences
FRANKLIN LAKES, N.J. , Dec. 21, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following upcoming ...